AR044688A1 - Agentes terapeuticos utiles para el tratamiento del dolor - Google Patents

Agentes terapeuticos utiles para el tratamiento del dolor

Info

Publication number
AR044688A1
AR044688A1 ARP040102043A ARP040102043A AR044688A1 AR 044688 A1 AR044688 A1 AR 044688A1 AR P040102043 A ARP040102043 A AR P040102043A AR P040102043 A ARP040102043 A AR P040102043A AR 044688 A1 AR044688 A1 AR 044688A1
Authority
AR
Argentina
Prior art keywords
halo
alkenyl
cycloalkyl
independently
members
Prior art date
Application number
ARP040102043A
Other languages
English (en)
Spanish (es)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR044688A1 publication Critical patent/AR044688A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP040102043A 2003-06-12 2004-06-11 Agentes terapeuticos utiles para el tratamiento del dolor AR044688A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47774403P 2003-06-12 2003-06-12

Publications (1)

Publication Number Publication Date
AR044688A1 true AR044688A1 (es) 2005-09-21

Family

ID=34061917

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102043A AR044688A1 (es) 2003-06-12 2004-06-11 Agentes terapeuticos utiles para el tratamiento del dolor

Country Status (28)

Country Link
US (3) US7683063B2 (OSRAM)
EP (3) EP1862458B1 (OSRAM)
JP (2) JP5269315B2 (OSRAM)
KR (2) KR20090008439A (OSRAM)
CN (2) CN1835751B (OSRAM)
AR (1) AR044688A1 (OSRAM)
AT (2) ATE413385T1 (OSRAM)
AU (1) AU2004255169B2 (OSRAM)
BR (1) BRPI0411241A (OSRAM)
CA (1) CA2528920C (OSRAM)
CY (1) CY1108738T1 (OSRAM)
DE (2) DE602004008069D1 (OSRAM)
DK (1) DK1862458T3 (OSRAM)
EA (1) EA009593B1 (OSRAM)
ES (1) ES2317623T3 (OSRAM)
GE (1) GEP20084488B (OSRAM)
IL (1) IL172418A (OSRAM)
IS (1) IS8142A (OSRAM)
MA (1) MA27908A1 (OSRAM)
MX (1) MXPA05013587A (OSRAM)
MY (1) MY142655A (OSRAM)
NO (1) NO20060192L (OSRAM)
PL (1) PL1862458T3 (OSRAM)
PT (1) PT1862458E (OSRAM)
SI (1) SI1862458T1 (OSRAM)
TW (1) TWI287010B (OSRAM)
WO (1) WO2005004866A1 (OSRAM)
ZA (1) ZA200508744B (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
WO2004103954A1 (ja) 2003-05-20 2004-12-02 Ajinomoto Co., Inc. アミド誘導体
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
US20050009841A1 (en) * 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
DE602004021206D1 (de) * 2003-07-24 2009-07-02 Euro Celtique Sa Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
HRP20090404T1 (hr) * 2003-07-24 2009-08-31 Euro-Celtique S.A. Spojevi piperidina i farmaceutski sastavi koji ih sadržavaju
TW200738232A (en) * 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
KR100801278B1 (ko) * 2006-08-29 2008-02-04 삼성전기주식회사 하이브리드형 광도파로 센서
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
JP5372913B2 (ja) * 2007-04-27 2013-12-18 パーデュー、ファーマ、リミテッド、パートナーシップ 疼痛治療に有効な治療薬
ES2571533T3 (es) 2007-04-27 2016-05-25 Purdue Pharma Lp Antagonistas de TRPV1 y usos de los mismos
KR20100007956A (ko) 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
EP2185538A2 (en) * 2007-08-09 2010-05-19 Abbott Laboratories Tetrahydropyridine carboxamide derivatives as trpvl antagonists
US8084616B2 (en) 2007-10-24 2011-12-27 Abbott Laboratories TRPV1 antagonists
KR20110027817A (ko) 2008-06-30 2011-03-16 노파르티스 아게 Ｍｇｌｕｒ 조절제를 포함하는 파킨슨병 치료용 조합물
EP2585446A4 (en) 2010-06-22 2013-12-25 Shionogi & Co COMPOUNDS HAVING ANTAGONIST ACTIVITY OF TRPV1 AND USES THEREOF
JP6130827B2 (ja) 2011-05-17 2017-05-17 塩野義製薬株式会社 ヘテロ環化合物
ES2620528T3 (es) 2011-06-22 2017-06-28 Purdue Pharma Lp Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos
EP2773779B1 (en) * 2011-11-04 2020-10-14 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
WO2013146970A1 (ja) * 2012-03-29 2013-10-03 第一三共株式会社 新規キノリン誘導体
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
AU2017281907B2 (en) * 2016-06-23 2021-10-21 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
JP6964506B2 (ja) * 2017-12-19 2021-11-10 ライオン株式会社 錠剤及び錠剤の製造方法
EP3731844A4 (en) 2017-12-27 2021-08-18 St. Jude Children's Research Hospital, Inc. PANTOTHENATE KINASES SMALL MOLECULE MODULATORS
AU2018397486B2 (en) 2017-12-27 2025-04-10 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
US12460178B2 (en) 2018-04-12 2025-11-04 Cellresearch Corporation Pte. Ltd. Method of inducing or improving wound healing properties of mesenchymal stem cells
TWI882956B (zh) * 2018-04-12 2025-05-11 新加坡商細胞研究私人有限公司 一種誘導或改善間質幹細胞傷口癒合特性的方法
RU2744162C1 (ru) * 2020-03-18 2021-03-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ПГФА Минздрава России) Анальгетическое средство на основе 5-(2-аминопропил)-6-оксо-3,4-дифенилпирроло[3,4-c]пиразола
KR102885259B1 (ko) 2020-07-31 2025-11-14 삼성전자주식회사 차폐 및 방열 구조를 포함하는 전자 장치
CN115536648B (zh) * 2021-06-29 2024-09-17 深圳开悦生命科技有限公司 一类抑制rna解旋酶dhx33的多环化合物及其应用
CN113061593B (zh) * 2021-04-02 2023-11-10 洛阳华荣生物技术有限公司 一种l-苹果酸脱氢酶突变体及其应用
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
CN114957214A (zh) * 2022-06-22 2022-08-30 九江善水科技股份有限公司 一种氯虫苯甲酰胺中间体的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB1363215A (en) * 1973-01-04 1974-08-14 Mullard Ltd Mechanical-electrical transducer
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5053595A (en) * 1982-12-01 1991-10-01 Metcal, Inc. Heat shrink sleeve with high mu material
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPH0680054B2 (ja) 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5198459A (en) 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
EP0636623B1 (en) * 1990-06-07 2001-08-16 AstraZeneca AB Indole derivatives as 5-HT1- like agonists
FR2676734B1 (fr) 1991-05-23 1995-05-19 Roussel Uclaf Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5232934A (en) 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
DE4234295A1 (de) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5762925A (en) 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
CA2224517A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
WO1998025908A1 (en) 1996-12-13 1998-06-18 Banyu Pharmaceutical Co., Ltd. Novel aminopyrazole derivatives
US6703362B1 (en) 1997-05-15 2004-03-09 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
WO1999009140A1 (en) 1997-08-20 1999-02-25 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
EP0943683A1 (en) 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
US6098369A (en) * 1998-07-17 2000-08-08 Bodolay; William A. Apparatus for attaching a reclosable fastener to a flexible material
ATE240316T1 (de) * 1998-12-23 2003-05-15 Lilly Co Eli Heteroaromatische amide als inhibitoren von faktor xa
CA2361149A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
US6689780B1 (en) 1998-12-23 2004-02-10 Eli Lilly And Company Heteroroaromatic amides as inhibitor of factor Xa
GB9907097D0 (en) 1999-03-26 1999-05-19 Novartis Ag Organic compounds
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1272187B1 (de) 2000-03-27 2008-07-30 Abbott GmbH & Co. KG Dopamin-d3-rezeptor-liganden zur behandlung von sucht
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
AR028782A1 (es) * 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
JP2003142681A (ja) * 2001-10-31 2003-05-16 Sony Corp 絶縁ゲート型電界効果トランジスタを有する半導体装置
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
DK1472225T3 (da) * 2002-02-01 2010-08-09 Euro Celtique Sa 2-Piperazinpyridiner, som er anvendelige til behandling af smerte
EP2033953A1 (en) 2002-02-15 2009-03-11 Glaxo Group Limited Vanilloid receptor modulators
US7582761B2 (en) 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7067509B2 (en) 2003-03-07 2006-06-27 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
WO2004103954A1 (ja) 2003-05-20 2004-12-02 Ajinomoto Co., Inc. アミド誘導体
TWI287010B (en) 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
US7129235B2 (en) * 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
US20050009841A1 (en) * 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
HRP20090404T1 (hr) * 2003-07-24 2009-08-31 Euro-Celtique S.A. Spojevi piperidina i farmaceutski sastavi koji ih sadržavaju
DE602004021206D1 (de) * 2003-07-24 2009-07-02 Euro Celtique Sa Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
JP5372913B2 (ja) * 2007-04-27 2013-12-18 パーデュー、ファーマ、リミテッド、パートナーシップ 疼痛治療に有効な治療薬

Also Published As

Publication number Publication date
IS8142A (is) 2005-11-23
EA009593B1 (ru) 2008-02-28
ATE413385T1 (de) 2008-11-15
MY142655A (en) 2010-12-15
KR20060012026A (ko) 2006-02-06
US7683063B2 (en) 2010-03-23
EP1631285B1 (en) 2007-08-08
AU2004255169B2 (en) 2010-08-26
EP1862458A3 (en) 2008-01-23
NO20060192L (no) 2006-02-07
CN1835751A (zh) 2006-09-20
MXPA05013587A (es) 2006-03-17
PT1862458E (pt) 2009-01-20
ES2317623T3 (es) 2009-04-16
JP2012021000A (ja) 2012-02-02
US8680118B2 (en) 2014-03-25
IL172418A0 (en) 2006-04-10
CY1108738T1 (el) 2014-07-02
EP1631285A1 (en) 2006-03-08
AU2004255169A1 (en) 2005-01-20
ZA200508744B (en) 2006-08-30
EP1862458A2 (en) 2007-12-05
TW200508216A (en) 2005-03-01
BRPI0411241A (pt) 2006-07-25
CN1835751B (zh) 2010-06-23
DE602004008069D1 (de) 2007-09-20
EP1862458B1 (en) 2008-11-05
KR20090008439A (ko) 2009-01-21
ATE369133T1 (de) 2007-08-15
US20070027159A1 (en) 2007-02-01
PL1862458T3 (pl) 2009-04-30
SI1862458T1 (sl) 2009-04-30
EA200501820A1 (ru) 2006-06-30
CN101863877A (zh) 2010-10-20
US8227467B2 (en) 2012-07-24
MA27908A1 (fr) 2006-05-02
CA2528920C (en) 2011-05-03
JP2007504284A (ja) 2007-03-01
US20130012541A1 (en) 2013-01-10
TWI287010B (en) 2007-09-21
EP2060260A1 (en) 2009-05-20
JP5269315B2 (ja) 2013-08-21
US20110152324A1 (en) 2011-06-23
IL172418A (en) 2011-03-31
EP1631285A4 (en) 2006-11-02
WO2005004866A1 (en) 2005-01-20
KR100896497B1 (ko) 2009-05-08
CA2528920A1 (en) 2005-01-20
DK1862458T3 (da) 2009-02-16
DE602004017658D1 (de) 2008-12-18
GEP20084488B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
AR044688A1 (es) Agentes terapeuticos utiles para el tratamiento del dolor
AR043324A1 (es) Derivados de benzoazolilpiperazina, composiciones que los contienen y su uso en el tratamiento del dolor.
AR037019A1 (es) Tioacetamidas sustituidas
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
RS51861B (sr) Heterociklični inhibitori mek-a
AR036103A1 (es) Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento
RU2018136336A (ru) Фторированное соединение циклопропиламина, способ получения, фармацевтическая композиция и ее использование
AR038971A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
HRP20241020T1 (hr) Makrociklički spoj koji služi kao wee1 inhibitor i njegove primjene
AR045082A1 (es) Compuestos de aminobenzofenona y su uso en tratamientos terapeuticos
AR053710A1 (es) Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR070520A1 (es) Derivados de azuleno nitrogenados,composiciones farmaceuticas que los contienen,proceso de preparacion y usos de los mismos para tratar trastornos metabolicos y digestivos,entre otros.
AR038883A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos
HRP20080492T3 (hr) Fenil-karboksamidni spojevi korisni za liječenje boli
BR9704970A (pt) Novos compostos de bifenil ou fenilpiridina substituídas um processo para sua preparação e composições farmacêuticas que os contêm
AR061581A1 (es) Compuestos de pirro[1,2-b]piridazinona,composiciones farmaceuticas que los contienen y usos para tratar hepatitis c.
AR046081A1 (es) Inhibidores heterociclicos de mek y uso de los mismos
AR065815A1 (es) Compuestos de dihidroindazol en el tratamiento de trastornos del hierro
AR060916A1 (es) Compuestos biciclicos antidiabeticos
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR038881A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos
AR069185A1 (es) Compuestos heterociclicos moduladores de gamma secretasa, composiciones farmaceuticas que los contienen y usos de los mismos para tratar trastornos del snc, tales como enfermedad de alzheimer y otras relacionadas con la deposicion de proteinas amiloides.
AR054787A1 (es) Derivados de piperidinas utiles como antagonistas de histamina h3
AR035366A1 (es) Derivados de la 2-fenoxi-1-(4-bencilpiperazin-1-il)-etan-1-ona, sus sales de monoclorhidrato y de diclorhidrato, un proceso para su preparacion, y un metodo de utilizacion de los mismos para la elaboracion de un producto radiofarmaceutico destinado al diagnóstico de la enfermedad de alzheimer en un

Legal Events

Date Code Title Description
FB Suspension of granting procedure